OBJECTIVES: To estimate neuropathic sign/symptom rates with initiation of combination antiretroviral therapy (cART) in HIV-infected ART-naive patients, and to investigate risk factors for: peripheral neuropathy and symptomatic peripheral neuropathy (SPN), recovery from peripheral neuropathy/SPN after neurotoxic ART (nART) discontinuation, and the absence of peripheral neuropathy/SPN while on nART. DESIGN: AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trial participants who initiated cART in randomized trials for ART-naive patients were annually screened for symptoms/signs of peripheral neuropathy. ART use and disease characteristics were collected longitudinally. METHODS:Peripheral neuropathy was defined as at least mild loss of vibration sensation in both great toes or absent/hypoactive ankle reflexes bilaterally. SPN was defined as peripheral neuropathy and bilateral symptoms. Generalized estimating equation logistic regression was used to estimate associations. RESULTS:Two thousand, one hundred and forty-one participants were followed from January 2000 to June 2007. Rates of peripheral neuropathy/SPN at 3 years were 32.1/8.6% despite 87.1% with HIV-1RNA 400 copies/ml or less and 70.3% with CD4 greater than 350 cells/μl. Associations with higher odds of peripheral neuropathy included older patient age and current nART use. Associations with higher odds of SPN included older patient age, nART use, and history of diabetes mellitus. Associations with lower odds of recovery after nART discontinuation included older patient age. Associations with higher odds of peripheral neuropathy while on nART included older patient age and current protease inhibitor use. Associations with higher odds of SPN while on nART included older patient age, history of diabetes, taller height, and protease inhibitor use. CONCLUSION: Signs of peripheral neuropathy remain despite virologic/immunologic control but frequently occurs without symptoms. Aging is a risk factor for peripheral neuropathy/SPN.
RCT Entities:
OBJECTIVES: To estimate neuropathic sign/symptom rates with initiation of combination antiretroviral therapy (cART) in HIV-infected ART-naivepatients, and to investigate risk factors for: peripheral neuropathy and symptomatic peripheral neuropathy (SPN), recovery from peripheral neuropathy/SPN after neurotoxicART (nART) discontinuation, and the absence of peripheral neuropathy/SPN while on nART. DESIGN:AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trial participants who initiated cART in randomized trials for ART-naive patients were annually screened for symptoms/signs of peripheral neuropathy. ART use and disease characteristics were collected longitudinally. METHODS:Peripheral neuropathy was defined as at least mild loss of vibration sensation in both great toes or absent/hypoactive ankle reflexes bilaterally. SPN was defined as peripheral neuropathy and bilateral symptoms. Generalized estimating equation logistic regression was used to estimate associations. RESULTS: Two thousand, one hundred and forty-one participants were followed from January 2000 to June 2007. Rates of peripheral neuropathy/SPN at 3 years were 32.1/8.6% despite 87.1% with HIV-1RNA 400 copies/ml or less and 70.3% with CD4 greater than 350 cells/μl. Associations with higher odds of peripheral neuropathy included older patient age and current nART use. Associations with higher odds of SPN included older patient age, nART use, and history of diabetes mellitus. Associations with lower odds of recovery after nART discontinuation included older patient age. Associations with higher odds of peripheral neuropathy while on nART included older patient age and current protease inhibitor use. Associations with higher odds of SPN while on nART included older patient age, history of diabetes, taller height, and protease inhibitor use. CONCLUSION: Signs of peripheral neuropathy remain despite virologic/immunologic control but frequently occurs without symptoms. Aging is a risk factor for peripheral neuropathy/SPN.
Authors: Kenneth A Lichtenstein; Carl Armon; Anna Baron; Anne C Moorman; Kathleen C Wood; Scott D Holmberg Journal: Clin Infect Dis Date: 2004-12-06 Impact factor: 9.079
Authors: Ronald J Ellis; Scott R Evans; David B Clifford; Lauren R Moo; Justin C McArthur; Ann C Collier; Constance Benson; Ron Bosch; David Simpson; Constantin T Yiannoutsos; Yijun Yang; Kevin Robertson Journal: J Neurovirol Date: 2005-12 Impact factor: 2.643
Authors: E A Childs; R H Lyles; O A Selnes; B Chen; E N Miller; B A Cohen; J T Becker; J Mellors; J C McArthur Journal: Neurology Date: 1999-02 Impact factor: 9.910
Authors: G Schifitto; M P McDermott; J C McArthur; K Marder; N Sacktor; D R McClernon; K Conant; B Cohen; L G Epstein; K Kieburtz Journal: Neurology Date: 2005-03-08 Impact factor: 9.910
Authors: H Bacellar; A Muñoz; E N Miller; B A Cohen; D Besley; O A Selnes; J T Becker; J C McArthur Journal: Neurology Date: 1994-10 Impact factor: 9.910
Authors: Eugene L Asahchop; William G Branton; Anand Krishnan; Patricia A Chen; Dong Yang; Linglong Kong; Douglas W Zochodne; Bruce J Brew; M John Gill; Christopher Power Journal: JCI Insight Date: 2018-12-06
Authors: Alejandro Arenas-Pinto; Jennifer Thompson; Godfrey Musoro; Hellen Musana; Abbas Lugemwa; Andrew Kambugu; Aggrey Mweemba; Dickens Atwongyeire; Margaret J Thomason; A Sarah Walker; Nicholas I Paton Journal: J Neurovirol Date: 2015-08-25 Impact factor: 2.643
Authors: Duaa Z Sakabumi; Raeanne C Moore; Bin Tang; Patrick A Delaney; John R Keltner; Ronald J Ellis Journal: J Acquir Immune Defic Syndr Date: 2019-04-15 Impact factor: 3.731
Authors: J Hafkin; C Modongo; C Newcomb; E Lowenthal; R R MacGregor; A P Steenhoff; H Friedman; G P Bisson Journal: Int J Tuberc Lung Dis Date: 2013-01-14 Impact factor: 2.373
Authors: Huichao Chen; David B Clifford; Lijuan Deng; Kunling Wu; Anthony J Lee; Ronald J Bosch; Sharon A Riddler; Ronald J Ellis; Scott R Evans Journal: J Neurovirol Date: 2013-12-03 Impact factor: 2.643